CTLA4 and neoplasm: This, together with results showing peak production of IFNg by intermediate-phase splenocytes and the potential to enhance IFNg production only by early treatment with anti CTLA-4, substantiates the recognition that immune activation prevails during the early-phase of tumor growth and that profound immune suppression prevails during the advanced-phase of tumor growth.